Mucin glycoproteins (MUC)

Mucin glycoproteins are high-molecular-weight, heavily glycosylated proteins that serve as the primary structural components of mucus, a viscoelastic gel covering epithelial surfaces (Thornton et al., 2008, Annu Rev Physiol [1]). They are categorized into secreted mucins (e.g., MUC5AC, MUC5B), which provide lubrication and trap pathogens, and membrane-tethered mucins (e.g., MUC1, MUC4), which participate in cell signaling and form the glycocalyx (Hollingsworth & Swanson, 2004, Nat Rev Cancer [2]). In respiratory diseases like COPD and cystic fibrosis, mucin hypersecretion leads to airway obstruction, while in various cancers, aberrant expression and glycosylation of mucins promote tumor progression and metastasis (Rose & Voynow, 2006, Physiol Rev [3]). Therapeutic strategies include mucolytic agents like N-acetylcysteine that break down the mucus structure by cleaving disulfide bonds to improve clearance (Balsamo et al., 2010, Eur Respir Rev [4]). Additionally, monoclonal antibodies are being developed to target mucin-expressing tumor cells for immunotherapy, leveraging the unique glycosylation patterns found in malignant tissues (Kufe, 2009, Nat Rev Cancer [5]).

Other names

MucinsMucous glycoproteinsMUC proteinsMucin-type glycoproteins

Mucolytic agents reduce mucus viscosity by cleaving disulfide bonds between mucin monomers; mucosecretolytic agents inhibit the production or secretion of mucins; and monoclonal antibodies target specific mucin epitopes (like MUC1) to induce antibody-dependent cellular cytotoxicity in malignant cells.